Effects of cannabinoid receptor activation on rabbit bisected vas deferens strips

Clinical and Experimental Pharmacology and Physiology

Volumn 32, Issue 9, 2005, Pages 702-707

  Barun, Süreyya ^a   Vural, Ismail Mert ^a   Dileköz, Ergin ^a   Ercan, Zeynep Sevim ^a   Sarioglu, Yusuf ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

212 2; AM 251; AM 630; Anandamide; Bisected vas deferens; Cannabinoids; CB1 receptor; CB2 receptor; Rabbit; WIN 55

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; NALOXONE; AMIDE; ARACHIDONIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID RECEPTOR; INDOLE DERIVATIVE; IODOPRAVADOLINE; MORPHOLINE DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ADRENERGIC TRANSMISSION; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; ELECTROSTIMULATION; MUSCLE TWITCH; NONHUMAN; RABBIT; STATISTICAL ANALYSIS; VAS DEFERENS; ADRENERGIC SYSTEM; ANIMAL; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; INNERVATION; MALE; MUSCLE CONTRACTION; PHYSIOLOGY; SMOOTH MUSCLE;

ANIMALS; ARACHIDONIC ACIDS; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; MALE; MORPHOLINES; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NALOXONE; NAPHTHALENES; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRAZOLES; RABBITS; RECEPTORS, CANNABINOID; SYMPATHETIC NERVOUS SYSTEM; VAS DEFERENS;

EID: 26944445871     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2005.04261.x     Document Type: Article

References (35)

1. Hillard CJ. Biochemistry and pharmacology of the endocannabinoids arachidonyl-etanolamie and 2-arachidonoylglycerol. Prostaglandins Other Lipid Mediat. 2000; 61: 3-18.
2. Kunos G, Jarai Z, Varga K, Liu J, Wang L, Wagner JA. Cardiovascular effects of endocannabinoids: The plot thickens. Prostaglandins Other Lipid Mediat. 2000; 61: 71-84.
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-4.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-5.
5. Galiegue S, Mary S, Marchand J et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 1995; 232: 54-61.
6. Pacheco M, Childers SR, Arnold R, Casino F, Ward SJ. Aminoalkylindoles: Actions on specific G-protein-linked receptors. J. Pharmacol. Exp. Ther. 1991; 257: 170-83.
7. Pertwee RG, Stevenson LA, Elrick DB, Mechoulam R, Corbett AD. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and myenteric plexus preparation of guinea-pig small intestine. Br. J. Pharmacol. 1992; 105: 980-4.
8. Pertwee RG, Fernando SR. Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br. J. Pharmacol. 1996; 118: 2053-8.
9. Sneddon P, Machaly M. Regional variation in purinergic and adrenergic responses in isolated vas deferens of rat, rabbit and guinea-pig. J. Auton. Pharmacol. 1992; 12: 421-8.
10. Burnstock G. Noradrenaline and ATP: Cotransmitters and neuromodulators. J. Physiol. Pharmacol. 1995; 46: 365-84.
11. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc. Natl Acad. Sci. USA 1992; 89: 3825-9.
12. Ishac EJN, Jiang L, Lake KD, Varga K, Abood ME, Kunos G. Inhibition of exocytotic noradrenaline release by pre-synaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 1996; 118: 2023-8.
13. Sneddon P, Westfall DP, Colby J, Fedan JS. A pharmacological investigation of the biphasic nature of the contractile response of rabbit and rat vas deferens to field stimulation. Life Sci. 1984; 35: 1903-12.
14. Rinaldi-Carmona M, Barth F, Heaulme M et al. SR141716A, potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994; 350: 240-4.
15. 2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol. 1997; 339: 53-61.
16. Gifford AN, Samiian L, Gatley SJ, Ashby Jr CR. Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically-evoked transmitter release from rat brain slices. Eur. J. Pharmacol. 1997; 324: 187-92.
17. White R, Hiley CR. The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br. J. Pharmacol. 1998; 125: 689-96.
18. 1 receptors in guinea-pig small intestine. Br. J. Pharmacol. 1996; 118: 2199-205.
19. Pertwee RG, Griffin G, Lainton JAH, Huffman JW. Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. Eur. J. Pharmacol. 1995; 284: 241-7.
20. 1 receptors in the rat and mouse. Eur. J. Pharmacol. 2000; 391: 151-61.
21. Von Kugelgen I, Starke K. Release of noradrenaline and ATP by electrical stimulation and nicotine in guinea-pig vas deferens. Naunyn Schmiedebergs Arch. Pharmacol. 1991; 344: 419-29.
22. Todorov LD, Bjur RA, Westfall DP. Temporal dissociation of the release of the sympathetic cotransmitters ATP and noradrenaline. Clin. Exp. Pharmacol. Physiol. 1994; 21: 931-2.
23. Todorov LD, Mihaylova-Todora S, Craviso GL, Bjur RA, Westfall DP. Evidence for the release of the cotransmitters ATP and noradrenaline from sympathetic nerves of the guinea-pig vas deferens. J. Physiol. 1996;496:731-48.
24. Nieri P, Martinotti E, Testai L, Martinelli C, Breschi MC. Effects of cannabinoids on non-adrenergic non-cholinergic-mediated relaxation in guinea pig trachea. Eur. J. Pharmacol. 2003; 475: 115-18.
25. Keith RA, Salama AI. Inhibition of presynaptic alpha-2-adrenoceptor and opioid receptor agonist responses in the rat vas deferens by chronic imipramine treatment. Naunyn Schmiedebergs Arch. Pharmacol. 1987;335:412-19.
26. Szallasi A, Di Marzo V. New perspectives on enigmatic vanilloid receptor. Trends Neurosci. 2000; 23: 491-7.
27. Wardle KA, Furey G, Sanger GJ. Pharmacological characterization of the vanilloid receptor in the rat vas deferens. J. Pharm. Pharmacol. 1996; 48: 285-91.
28. Zygmunt PM, Petersson J, Andersson DA et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999; 400: 452-7.
29. Smart D, Gunthorpe MJ, Jerman JC et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 2000; 129: 2227-30.
30. Stone TW. The effects of 4-aminopyridine on the isolated vas deferens and its effects onhe inhibitory properties of adenosine, morphine, noradrenaline and γ-aminobutyric acid. Br. J. Pharmacol. 1981; 73: 791-6.
31. Stjarne L, Lundberg JM, Astrand P, Neuropeptide Y. A cotransmitter with noradrenaline and adenosine 5′-triphosphate in the sympathetic nerves of the mouse vas deferens? A biochemical, physiological and electropharmacological study. Neuroscience 1986; 18: 151-66.
32. Smith CFC, Rowland PB. Dopamine receptors in the mouse vas deferens. Arch. Int. Pharmacodyn. 1989; 299: 144-54.
33. 2-receptors of sympathetic neuro-effector transmission in the mouse isolated vas deferens. Naunyn Schmiedebergs Arch. Pharmacol. 1989; 340: 522-32.
34. Seong YH, Baba A, Matsuda T, Iwata H. 5-Hydroxytryptamine modulation of electrically induced twitch responses of mouse vas deferens: Involvement of multiple 5-hydroxytriptamine receptors. J. Pharmacol. Exp. Ther. 1990; 254: 1012-16.
35. Pertwee RG, Griffin G. A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens. Eur. J. Pharmacol. 1995; 272: 67-72.